Abstract

Staphylococcus aureus (SA) leukocidin LukED belongs to a family of bicomponent pore forming toxins that play important roles in SA immune evasion and nutrient acquisition. LukED targets specific G protein-coupled chemokine receptors to lyse human erythrocytes (red blood cells) and leukocytes (white blood cells). The first recognition step of receptors is critical for specific cell targeting and lysis. The structural and molecular bases for this mechanism are not well understood but could constitute essential information to guide antibiotic development. Here, we characterized the interaction of LukE with chemokine receptors ACKR1, CCR2 and CCR5 using a combination of structural, pharmacological and computational approaches. First, crystal structures of LukE in complex with a small molecule mimicking sulfotyrosine side chain (p-cresyl sulfate) and with peptides containing sulfotyrosines issued from receptor sequences revealed the location of receptor sulfotyrosine binding sites in the toxins. Then, by combining previous and novel experimental data with protein docking, classical and accelerated weight histogram (AWH) molecular dynamics we propose models of the ACKR1-LukE and CCR5-LukE complexes. This work provides novel insights into chemokine receptor recognition by leukotoxins and suggests that the conserved sulfotyrosine binding pocket could be a target of choice for future drug development.

Data availability

Diffraction data have been deposited in PDB under the accession codes 7P8T, 7P8S, 7P8U, 7P8X and 7P93. Source Data files containing the computational models of the ACKR1-LukE and CCR5-LukE complexes in Figures 6 and 7 have been provided as pdb files. Figure 2 - Source Data 1 contain the numerical data used to generate the figure.

Article and author information

Author details

  1. Paul Lambey

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Omolade Otun

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Xiaojing Cong

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  4. François Hoh

    Centre de Biochimie Structurale, CNRS UMR 5048-INSERM 1054- University of Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Luc Brunel

    Centre de Biochimie Structurale, CNRS UMR 5048-INSERM 1054- University of Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Pascal Verdié

    Centre de Biochimie Structurale, CNRS UMR 5048-INSERM 1054- University of Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5807-0293
  7. Claire M Grison

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Fanny Peysson

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Sylvain Jeannot

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Thierry Durroux

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Cherine Betara

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Sébastien Granier

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    For correspondence
    sebastien.granier@igf.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
  13. Cédric Leyrat

    Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France
    For correspondence
    cedric.leyrat@igf.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0189-0562

Funding

Agence Nationale de la Recherche (ANR-17-CE15-0002-01)

  • Cédric Leyrat

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Lambey et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 225
    downloads

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Paul Lambey
  2. Omolade Otun
  3. Xiaojing Cong
  4. François Hoh
  5. Luc Brunel
  6. Pascal Verdié
  7. Claire M Grison
  8. Fanny Peysson
  9. Sylvain Jeannot
  10. Thierry Durroux
  11. Cherine Betara
  12. Sébastien Granier
  13. Cédric Leyrat
(2022)
Structural insights into recognition of chemokine receptors by Staphylococcus aureus leukotoxins
eLife 11:e72555.
https://doi.org/10.7554/eLife.72555

Share this article

https://doi.org/10.7554/eLife.72555

Further reading

    1. Cell Biology
    2. Microbiology and Infectious Disease
    Clément Mazeaud, Stefan Pfister ... Laurent Chatel-Chaix
    Research Article

    Zika virus (ZIKV) infection causes significant human disease that, with no approved treatment or vaccine, constitutes a major public health concern. Its life cycle entirely relies on the cytoplasmic fate of the viral RNA genome (vRNA) through a fine-tuned equilibrium between vRNA translation, replication, and packaging into new virions, all within virus-induced replication organelles (vROs). In this study, with an RNA interference (RNAi) mini-screening and subsequent functional characterization, we have identified insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) as a new host dependency factor that regulates vRNA synthesis. In infected cells, IGF2BP2 associates with viral NS5 polymerase and redistributes to the perinuclear viral replication compartment. Combined fluorescence in situ hybridization-based confocal imaging, in vitro binding assays, and immunoprecipitation coupled to RT-qPCR showed that IGF2BP2 directly interacts with ZIKV vRNA 3’ nontranslated region. Using ZIKV sub-genomic replicons and a replication-independent vRO induction system, we demonstrated that IGF2BP2 knockdown impairs de novo vRO biogenesis and, consistently, vRNA synthesis. Finally, the analysis of immunopurified IGF2BP2 complex using quantitative mass spectrometry and RT-qPCR revealed that ZIKV infection alters the protein and RNA interactomes of IGF2BP2. Altogether, our data support that ZIKV hijacks and remodels the IGF2BP2 ribonucleoprotein complex to regulate vRO biogenesis and vRNA neosynthesis.

    1. Microbiology and Infectious Disease
    Linkang Wang, Haiyan Wang ... Ping Qian
    Research Article

    Bacillus velezensis is a species of Bacillus that has been widely investigated because of its broad-spectrum antimicrobial activity. However, most studies on B. velezensis have focused on the biocontrol of plant diseases, with few reports on antagonizing Salmonella Typhimurium infections. In this investigation, it was discovered that B. velezensis HBXN2020, which was isolated from healthy black pigs, possessed strong anti-stress and broad-spectrum antibacterial activity. Importantly, B. velezensis HBXN2020 did not cause any adverse side effects in mice when administered at various doses (1×107, 1×108, and 1×109 CFU) for 14 days. Supplementing B. velezensis HBXN2020 spores, either as a curative or preventive measure, dramatically reduced the levels of S. Typhimurium ATCC14028 in the mice’s feces, ileum, cecum, and colon, as well as the disease activity index (DAI), in a model of infection caused by this pathogen in mice. Additionally, supplementing B. velezensis HBXN2020 spores significantly regulated cytokine levels (Tnfa, Il1b, Il6, and Il10) and maintained the expression of tight junction proteins and mucin protein. Most importantly, adding B. velezensis HBXN2020 spores to the colonic microbiota improved its stability and increased the amount of beneficial bacteria (Lactobacillus and Akkermansia). All together, B. velezensis HBXN2020 can improve intestinal microbiota stability and barrier integrity and reduce inflammation to help treat infection by S. Typhimurium.